CSL Behring Foundation

CSL Behring is a global leader in the biotherapeutics industry, specializing in the development and manufacture of therapies derived from human plasma and recombinant technologies. As a primary subsidiary of CSL Limited, the company focuses on treating rare and serious diseases, including coagulation disorders, primary immunodeficiencies, and hereditary angioedema. Their extensive portfolio features market-leading products such as Hizentra, Privigen, and Haegarda, as well as the first-ever gene therapy for hemophilia B, Hemgenix. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma, ensuring a stable supply of raw materials for its life-saving treatments. The company maintains a robust global presence with major R&D and manufacturing hubs in the United States, Germany, and Switzerland.